See appendix for details.
Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire
Article first published online: 7 JUL 2011
Copyright © 2011 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 20, Issue 12, pages 1303–1310, December 2011
How to Cite
Jaquet, A., Djima, M. M., Coffie, P., Kacou, H. D., Eholie, S. P., Messou, E., Minga, A., Guehi, C., Yavo, J. C., Bissagnene, E., Dabis, F., Ekouevi, D. K. and for the IeDEA West Africa Collaboration (2011), Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire. Pharmacoepidem. Drug Safe., 20: 1303–1310. doi: 10.1002/pds.2182
See appendix for details.
- Issue published online: 22 NOV 2011
- Article first published online: 7 JUL 2011
- Manuscript Accepted: 4 MAY 2011
- Manuscript Revised: 27 APR 2011
- Manuscript Received: 25 JAN 2011
- National Cancer Institute (NCI). Grant Number: 5U01AI069919
- Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
- National Institute of Allergy and Infectious Diseases (NIAID)
- sub-Saharan Africa
Although antiretroviral treatment (ART)–related adverse drug reactions (ADR) are documented in industrialised countries, there is no pre-existing surveillance system dedicated to ADR monitoring in most African countries. We assessed knowledge towards pharmacovigilance among ART prescribers and available capacity of HIV clinics to conduct ADR monitoring in Abidjan, Côte d'Ivoire.
A questionnaire was administered to ART prescribers to assess their knowledge towards the occurrence of ADRs. A retrospective ADR survey was also conducted based on a data query of treatment modification/interruptions in three HIV clinics. Clinical monitors went back to medical charts to review and validate the reasons of the treatment modification/interruptions.
Of the 81 ART prescribers interviewed, 25 (31%) declared not grading ADRs and 12 (14.8%) declared notifying ADRs to the national regulatory authorities. Among 5252 adult ART-treated patients who attended the participating clinics in 2008, 599 treatment modifications were identified. Reasons for treatment modification/interruptions identified in the electronic database were documented in the medical charts in 554 cases (92.5%), ADR accounting for 273 cases (45.5%). Toxicity related to ART was graded in only 58 cases (21%) in the medical charts.
This study describes challenges limiting the implementation of reliable pharmacovigilance activities in HIV clinics in Côte d'Ivoire. The lack of knowledge of ART prescribers concerning ADR grading does not support the spontaneous reporting of ADRs. Using treatment modification/interruptions for ADR monitoring appears feasible, but improvements are needed to respond to key questions related to drug toxicities in the context of ART scale-up in Africa. Copyright © 2011 John Wiley & Sons, Ltd.